Costs and consequences of different chemotherapy regimens in metastatic colorectal cancer.

Costs and consequences of different chemotherapy regimens in metastatic colorectal cancer.

An economic sub-study was run alongside a large multi-centre randomised trial (MRC-CR06) comparing three chemotherapy regimens; de Gramont, Lokich and raltitrexed in patients with metastatic colorectal cancer. Patients in six of 45 centres in the main trial were approached to take part in the sub-st...

Bibliografske podrobnosti
Main Authors:	Hale, J, Cohen, DR, Maughan, T, Stephens, R
Format:	Journal article
Jezik:	English
Izdano:	2002

Podobne knjige/članki

Comparison of survival, palliation, and quality of life with three chemotherapy regimens in metastatic colorectal cancer: a multicentre randomised trial.
od: Maughan, T, et al.
Izdano: (2002)

Cetuximab plus Irinotecan as third line chemotherapy for metastatic colorectal cancer
od: Moe, M, et al.
Izdano: (2008)

Chemotherapy-free intervals for patients with metastatic colorectal cancer remain an option.
od: Maughan, T, et al.
Izdano: (2010)

A cost comparison of biologic treatment regimens for metastatic colorectal cancer in Italy
od: Sergio Iannazzo, et al.
Izdano: (2017-10-01)

Combination chemotherapy for metastatic colorectal cancer
od: Koehne Claus-Henning
Izdano: (2003-01-01)

INTEGRATION OF BEVACIZUMAB IN METASTATIC COLORECTAL CANCER CHEMOTHERAPY REGIMENS IN 2 CLINICAL CENTERS IN MOSCOW AND SAINT PETERSBURG
od: N. V. Dobrova, et al.
Izdano: (2015-02-01)

Cetuximab therapy in first-line metastatic colorectal cancer and intermittent palliative chemotherapy: review of the COIN trial.
od: Adams, R, et al.
Izdano: (2008)

Immunotherapy regimens for metastatic colorectal carcinomas
od: Babar Bashir, et al.
Izdano: (2018-02-01)

Incidence of Chemotherapy-Induced Fever and Neutropenia in Different Chemotherapy Regimens in Hospitalized Patients with Non-Metastatic Breast Cancer
od: Mehran Sharifi, et al.
Izdano: (2024-12-01)

Management of patients with metastatic colorectal cancer: economic consequences of different treatment programs
od: Stefania Lopatriello, et al.
Izdano: (2009-09-01)

Using bevacizumab with different chemotherapeutic regimens in metastatic colorectal cancer: balancing utility with low toxicity
od: G. Chong, et al.
Izdano: (2010-09-01)

The impact of combining cetuximab with the traditional chemotherapy regimens on clinical effectiveness in metastatic colorectal cancer: a systematic review and meta-analysis
od: Marryam Azeem, et al.
Izdano: (2025-02-01)

Evolution of Adjuvant Chemotherapy and Efficacy of Commonly Used Regimens in Colorectal Cancer
od: S.M. Adiga, et al.
Izdano: (2012-04-01)

Cost‐effectiveness analysis of continuing bevacizumab plus chemotherapy versus chemotherapy alone after first progression of metastatic colorectal cancer
od: Yulian Li, et al.
Izdano: (2024-01-01)

Raltitrexed Chemotherapy Regimen Plus Bevacizumab as Second-Line Treatment for Metastatic Colorectal Cancer: A Prospective Multicenter Phase II Trial
od: Sheng Li MD, et al.
Izdano: (2024-08-01)

The Effect Of Chemotherapy On Malnutrition In Geriatric Group With Metastatic Colorectal Cancer
od: Esat Namal
Izdano: (2019-01-01)

Study on intraperitoneal chemotherapy in treatment of peritoneal metastatic colorectal cancer
od: CHENG Guozhu, CAI Guoxiang
Izdano: (2021-01-01)

A pilot study of the use of Oxaliplatin in metastatic colorectal cancer at Velindre
od: Mitra, S, et al.
Izdano: (2001)

Chemotherapy in Metastatic NSCLC – New Regimens (Pemetrexed, nab-Paclitaxel)
od: Vera eHirsh, et al.
Izdano: (2014-07-01)

An Observational Study of Trifluridine/Tipiracil-Containing Regimen Versus Regorafenib-Containing Regimen in Patients With Metastatic Colorectal Cancer
od: Meng-Che Hsieh, et al.
Izdano: (2022-05-01)

Comparison of intermittent and continuous palliative chemotherapy for advanced colorectal cancer: a multicentre randomised trial.
od: Maughan, T, et al.
Izdano: (2003)

Chemotherapy for older patients with colorectal cancer Reply
od: Seymour, M, et al.
Izdano: (2011)

Real-world treatment patterns and clinical outcomes for chemotherapy-based regimens in first-line MSI-H/dMMR metastatic colorectal cancer
od: Mayur M. Amonkar, et al.
Izdano: (2023-01-01)

Triple combination of irinotecan + oxaliplatin + 5-fluorouracil as first-line chemotherapy for metastatic colorectal cancer: first experience with a new treatment regimen
od: A. D. Darenskaya, et al.
Izdano: (2018-05-01)

Management of the asymptomatic primary in the palliative treatment of metastatic colorectal cancer.
od: Clements, D, et al.
Izdano: (2009)

Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial.
od: Seymour, M, et al.
Izdano: (2011)

Chemotherapy for colorectal cancer in the metastatic and adjuvant setting: past, present and future.
od: Sabharwal, A, et al.
Izdano: (2007)

Chemotherapy in the Setting of Severe Liver Dysfunction in Patients with Metastatic Colorectal Cancer
od: Pashtoon Murtaza Kasi, et al.
Izdano: (2015-01-01)

Factors influencing choice of chemotherapy in metastatic colorectal cancer (mCRC)
od: Rossi L, et al.
Izdano: (2013-11-01)

Pharmacoeconomic-guided choice of systemic chemotherapy in metastatic colorectal cancer patients
od: M. Yu. Fedyanin, et al.
Izdano: (2017-09-01)

Risk of cardiovascular disease among different fluoropyrimidine-based chemotherapy regimens as adjuvant treatment for resected colorectal cancer
od: Wen-Kuan Huang, et al.
Izdano: (2022-08-01)

Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial.
od: Seymour, M, et al.
Izdano: (2007)

Erratum on: Chemotherapy in metastatic NSCLC – new regimens (pemetrexed, nab-paclitaxel)
od: Frontiers in Oncology Editorial Office
Izdano: (2014-10-01)

The results of primary chemotherapy of TS-1/cisplatin regimen in unresectable or metastatic gastric cancer patients
od: Jung Hyun Song, et al.
Izdano: (2014-06-01)

Healthcare costs in patients with metastatic lung cancer receiving chemotherapy
od: Vera-Llonch Montserrat, et al.
Izdano: (2011-11-01)

In vitro 3D microfluidic peritoneal metastatic colorectal cancer model for testing different oxaliplatin-based HIPEC regimens
od: Canda Aras Emre, et al.
Izdano: (2024-02-01)

Cost-effectiveness analysis of first-line combination chemotherapy regimens for metastatic pancreatic cancer and evidence-based pricing strategy of liposomal irinotecan in China
od: Zuojuan Xiang, et al.
Izdano: (2024-12-01)

Different Chemotherapy Regimens in the Management of Advanced or Metastatic Urothelial Cancer: a Bayesian Network Meta-Analysis of Randomized Controlled Trials
od: Yi Wang, et al.
Izdano: (2018-10-01)

The cost-effectiveness of adjuvant chemotherapy for early breast cancer: A comparison of no chemotherapy and first, second, and third generation regimens for patients with differing prognoses.
od: Campbell, H, et al.
Izdano: (2011)

The cost-effectiveness of adjuvant chemotherapy for early breast cancer: A comparison of no chemotherapy and first, second, and third generation regimens for patients with differing prognoses
od: Campbell, H, et al.
Izdano: (2011)